Dupilumab Effects Against Aeroallergen Challenge

Conditions

Dupilumab — DRUG
Dupixent is an interleukin-4 receptor alpha antagonist
House Dust Mites (HDM) — OTHER
House Dust Mites used to challenge subjects using an aeroallergen challenge chamber
Placebo — OTHER
Inert placebo administered to placebo arms of study.

The trial involves two interventions: (i) exposure to HDM in the ACC and (ii) administration of dupilumab/placebo for dupilumab.

Active Comparator: Adaptive Phenotypes randomized to study drug
This group will be comprised of the Adaptive-A and Adaptive-B subgroup and will consist of the adaptive phenotype participants identified during the initial HDM ACC challenge, administered the study drug.
Experimental: Maladaptive Phenotypes randomized to study drug
This group will be comprised of the Maladaptive-A and Maladaptive-B subgroup and will consist of the maladaptive phenotype participants identified during the initial HDM ACC challenge administered the study drug.
Placebo Comparator: Adaptive Phenotype randomized to placebo
This group will be comprised of the Adaptive-A and Adaptive-B subgroup and will consist of the adaptive phenotype participants identified during the initial HDM ACC challenge, administered the placebo.
Placebo Comparator: Maladaptive Phenotype randomized to placebo
This group will be comprised of the Maladaptive-A and Maladaptive-B subgroup and will consist of the maladaptive phenotype participants identified during the initial HDM ACC challenge administered the placebo.

Overall change in ACC HDM exposure-induced nasal airway gene expression profile [ Time Frame: Baseline to 18 weeks ]

Facility	City	State	ZIP	Site coordinators
Biogenics Research Chamber	San Antonio	Texas	78229	Robert L Jacobs, MD [email protected] Sunil K Ahuja, MD [email protected] 210-567-4823
University of Texas Health Science Center at San Antonio	San Antonio	Texas	78229	-

By research site